Steven Maron, MD
Hematology & Oncology · New York, NYNPI 1619266186
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $29,565 of the $42,007 with a category attached, or 70.4%. 8 manufacturers reported payments, led by Amgen at 35.6% of the total.
Across 42 payments — averaging $1000.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$15K
- Merck$11K
- Novartis$10K
- Daiichi Sankyo Inc.$4K
- AstraZeneca$1K
- Beigene USA, Inc.$1K
- plus $188 from 2 others
Across 108 payments — averaging $21,497 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$1.3M
- Janssen Research & Development, LLC$559K
- Boehringer Ingelheim$363K
- Bayer$101K
- Boehringer Ingelheim Pharma GmbH & Co.kg$6K
- Boehringer Ingelheim International GmbH$3K
What the payments were for
- Consulting fees$29,56570%
- Travel & lodging$11,20327%
- Food & beverage$1,2393%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 7 | $14,950 |
| Merck | 16 | $10,843 |
| Novartis | 3 | $9,543 |
| Daiichi Sankyo Inc. | 2 | $4,110 |
| AstraZeneca | 11 | $1,357 |
| Beigene USA, Inc. | 1 | $1,017 |
| Exelixis Inc. | 1 | $108 |
| Genentech USA, Inc. | 1 | $80 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$42,007 in reported general payments places this provider in the 85th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 17 | $20,609 |
| Sucralfate | 21 | $4,219 |
| Pantoprazole Sodium | 79 | $1,046 |
| Prochlorperazine Maleate | 13 | $336 |
| Ondansetron Hcl | 30 | $334 |
| Metoclopramide Hcl | 20 | $176 |
| Ondansetron OdtOndansetron | 11 | $176 |
| Olanzapine | 19 | $162 |
| Omeprazole | 16 | $130 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in New York
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Ross LevineNew York$968K
- Joshua SabariNew York$761K
- Gail RobozNew York$738K
- Jeffrey LaurenceNew York$640K
- John AllanNew York$580K
- Ilan ShapiraNew York$475K
- John MascarenhasNew York$456K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.